15581-80-3Relevant articles and documents
3,3,10,10-tetramethyl-1,2-dithia-5,8-diazacyclodeca-4,8-diene
Lo, Jem-Mau,Mostafa, Golam,Chang, Ling-Yin,Liao, Fen-Ling,Lu, Tian-Huey
, p. o276-o277 (2004)
The synthesis of C10H18N2S2 was described. It was observed that the molecule of the compound possess a local twofold axis and the arrangement of the S2N2 donor atoms in the macrocycle is anticlinal. The cyclic structure of the given compound is in contrast with the linear structure of the diamine-dithiol compound obtained from a reduction reaction. It was found that the H atoms bonded to C atoms were positioned geometrically in the compound.
First examples of oxidizing aldehydes to carboxylic acids in the presence of a tertiary disulfide functional group: Synthesis of novel diacid-disulfides
Fang, Xinqin,Bandarage, Upul K.,Wang, Tiansheng,Schroeder, Joseph D.,Garvey, David S.
, p. 489 - 492 (2003)
The disulfide functionality exists in numerous organic compounds of interest in both chemistry and biology. In view of the fact that the disulfide function is highly susceptible to further oxidation by a broad range of agents, conducting a chemoselective
Hayashi
, p. 5,9 (1970)
RADIOACTIVELY LABELED SUBSTANCE
-
, (2012/03/26)
Provided are: a radiolabeled drug, which is efficiently accumulated in a target and has high in vivo stability; and diagnosis and treatment each using the radiolabeled drug. Specifically provided are: a radiolabeled drug showing increased accumulation in a target site, which comprises a complex composed of a ligand that is bound to a compound capable of binding to a target molecule and forms a polycoordinated complex with a metal (e.g., technetium or rhenium) and a radionuclide of the metal; the radiolabeled drug for diagnosis or treatment; a ligand for preparing the radiolabeled drug; a kit that comprises a drug comprising the ligand and a drug comprising a radionuclide of a metal, as separate package units; and a method of increasing accumulation of a radiolabeled drug in a target site, comprising using the above-mentioned radiolabeled drug.
Nitrostated and nitrosylated prostaglandins, compositions and methods of use
-
Page/Page column 42, (2008/06/13)
The present invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.